MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
13 janv. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive...